S. Noviello et al., In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci, J ANTIMICRO, 48(2), 2001, pp. 283-286
Gram-positive cocci are a major cause of nosocomial bacteraemias and are of
ten resistant to most antibiotics. The emergence of enterococci with reduce
d susceptibility to vancomycin has created an urgent need for novel antibio
tics to combat infections associated with these bacteria. In this study the
in vitro activity of LY333328 (oritavancin), a semi-synthetic glycopeptide
, was evaluated. LY333328 was effective against all strains of staphylococc
i, streptococci and enterococci tested. A combination of LY333328 and cipro
floxacin was additive for 50% of Enterococcus faecium strains resistant to
both vancomycin and ciprofloxacin, and for 100% of vancomycin-susceptible a
nd either ciprofloxacin-susceptible or -resistant strains.